Glucocorticoid receptor alpha isoform (GRα) (GRα)

The Glucocorticoid receptor (GR), specifically the alpha isoform (GRα), is a ubiquitous ligand-dependent transcription factor that serves as the primary mediator of glucocorticoid action in humans [1, 3, 10]. Encoded by the NR3C1 gene, GRα regulates a vast array of physiological processes, including glucose and lipid metabolism, immune system modulation, and the body's response to stress via the hypothalamic-pituitary-adrenal (HPA) axis [1, 2, 9]. Upon binding to endogenous cortisol or synthetic glucocorticoids, the receptor translocates from the cytoplasm to the nucleus, where it modulates the expression of approximately 10-20% of the human genome through transactivation of anti-inflammatory genes and transrepression of pro-inflammatory transcription factors like NF-κB and AP-1 [1, 6, 7, 11]. GRα is a critical therapeutic target for a wide range of conditions, including asthma, rheumatoid arthritis, and hematologic malignancies, due to its potent anti-inflammatory and pro-apoptotic effects [4, 11, 14]. Drugs targeting GRα include a wide range of synthetic agonists like dexamethasone and prednisone, which are used for their anti-inflammatory properties, as well as antagonists like mifepristone, which are used in the management of hypercortisolism [1, 7, 14]. However, chronic pharmacological activation of the receptor is associated with significant safety concerns, such as iatrogenic Cushing's syndrome, osteoporosis, and secondary adrenal insufficiency [1, 5, 14].

Other names

NR3C1GCRGCCRGlucocorticoid receptorGRGlucocorticoid receptor alpha

Agonism, Antagonism, Transactivation, Transrepression, Non-genomic signaling